AMPH Q3 2019 Earnings — Amphastar Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMPHAmphastar Pharmaceuticals, Inc.

$860M

Q3 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$80M+6.1% YoY

Gross Profit

$35M44.0% margin

Operating Income

$2M3.0% margin

Net Income

$1M1.6% margin

EPS (Diluted)

$0.03

QoQ Revenue Growth

+1.4%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$21M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$586M

Total Liabilities

$152M

Stockholders' Equity

$389M

Cash & Equivalents

$86M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$80M	$76M	+6.1%
Gross Profit	$35M	$29M	+20.5%
Operating Income	$2M	$3M	-5.7%
Net Income	$1M	$2M	-45.2%

Revenue Segments

Active Pharmaceutical Ingredient Segment

$4M100%

Geographic Segments

U

$76M100%

C

$59,0000%